ARTICLE | Finance

Ebb & Flow

June 9, 2008 7:00 AM UTC

Having gotten his hands on 215 pages of documents fromBiogen Idec (NASDAQ:BIIB) under judicial order by the Delaware Chancery Court, activist investor Carl Icahn last week leveled new charges that at least one potential acquirer walked away from the bidding process rather than work under the conditions demanded by the biotech.

Icahn, who has been pressuring Biogen Idec to put itself up for sale, had sought the documents after the company's efforts to sell itself foundered (see BioCentury, May 26). ...